Clinical Trial

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A\*02:01 in patients with relapsed or refractory AML.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-16; most recent amendment 2026-04-13.
Status change: Not Yet Recruiting → Recruiting 2024-08-14
Trial Details
NCT Number NCT06424340
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Leukemia, Myeloid, Acute
Enrollment 29 participants
Start Date 2024-08-01
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-16